🇺🇸 FDA
Patent

US 9441041

Use of antagonists of the interaction between HIV GP120 and α4β7 integrin

granted A61KA61K2039/505A61K38/12

Quick answer

US patent 9441041 (Use of antagonists of the interaction between HIV GP120 and α4β7 integrin) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/505, A61K38/12, A61K39/3955, A61K45/06